Handelsbanken Fonder AB Has $1.54 Million Position in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Handelsbanken Fonder AB increased its holdings in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 10.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,100,000 shares of the biotechnology company’s stock after acquiring an additional 100,000 shares during the period. Handelsbanken Fonder AB’s holdings in Seres Therapeutics were worth $1,540,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Simplicity Solutions LLC acquired a new stake in shares of Seres Therapeutics during the 3rd quarter valued at about $27,000. Hudson Bay Capital Management LP boosted its position in Seres Therapeutics by 127.3% in the third quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock valued at $4,760,000 after buying an additional 1,119,800 shares in the last quarter. SG Americas Securities LLC acquired a new position in Seres Therapeutics in the fourth quarter valued at about $73,000. Aigen Investment Management LP boosted its position in Seres Therapeutics by 577.1% in the third quarter. Aigen Investment Management LP now owns 75,241 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 64,128 shares in the last quarter. Finally, Graham Capital Management L.P. boosted its position in Seres Therapeutics by 731.3% in the third quarter. Graham Capital Management L.P. now owns 206,838 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 181,957 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Oppenheimer reduced their price target on shares of Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 6th. Chardan Capital reduced their price target on shares of Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 6th.

Seres Therapeutics Trading Up 11.1 %

Shares of MCRB stock opened at $0.83 on Friday. Seres Therapeutics, Inc. has a 1 year low of $0.54 and a 1 year high of $6.65. The firm’s 50 day moving average is $0.84 and its 200-day moving average is $1.09. The firm has a market capitalization of $124.58 million, a price-to-earnings ratio of -0.92 and a beta of 2.23.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.50 million. On average, equities research analysts forecast that Seres Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Seres Therapeutics Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.